Advertisement

Journal of Molecular Neuroscience

, Volume 68, Issue 1, pp 38–48 | Cite as

LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP

  • Yi Shi
  • Decheng Geng
  • Yu Zhang
  • Min Zhao
  • Yan Wang
  • Yang Jiang
  • Rutong YuEmail author
  • Xiuping ZhouEmail author
Article

Abstract

We previously reported that LATS2, the upstream serine/threonine kinase of Yes-associated protein (YAP), is downregulated in gliomas and exhibits negative correlation with the prognosis of glioma patients. In this work, we aimed to explore the role and mechanism of large tumor suppressor kinase (LATS2) in the progression of malignant gliomas. We found that over-expression of LATS2 inhibited glioma cell proliferation and migration/invasion, while LATS2 downregulation promoted them. Mechanistically, LATS2 promoted the phosphorylation of YAP without affecting YAP mRNA expression. Inconsistent with some previous reports, both YAPWT and YAP5SA did not affect the level of LATS2, suggesting that LATS2 did not form a feedback loop with YAP in gliomas. Furthermore, mammalian Ste20-like kinases (MST1) over-expression did not affect the phosphorylation of YAP, suggesting that MST1 may not be the essential upstream serine/threonine kinase of Hippo/YAP pathway in gliomas. Together, LATS2 inhibits glioma cell proliferation and migration/invasion by inactivating YAP.

Keywords

Glioma LATS2 Proliferation Migration/invasion YAP 

Notes

Funding Information

This study was funded by National Natural Science Foundation of China (No. 81672489; No. 81472345; No. 81872053).

Compliance with Ethical Standards

Glioma tissues diagnosed according to the 2007 World Health Organization classification were collected from Brain Hospital, Affiliated Hospital of Xuzhou Medical University during year 2014–2015. There are 55 cases of glioma samples, including 22 cases of astrocytomas (grade II), 17 cases of anaplastic astrocytomas (grade III), and 16 cases of glioblastomas (grade IV). Eighteen nontumorous brain tissues were obtained from internal decompression of patients with cerebral injury. Written informed consent was obtained from each patient, and the study was approved by the ethics committee of the hospital.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. An Y, Kang Q, Zhao Y, Hu X, Li N (2013) Lats2 modulates adipocyte proliferation and differentiation via hippo signaling. PLoS One 8:e72042CrossRefGoogle Scholar
  2. Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD (2005) Human LATS1 is a mitotic exit network kinase. Cancer Res 65:6568–6575CrossRefGoogle Scholar
  3. Chao Y, Wang Y, Liu X, Ma P, Shi Y, Gao J, Shi Q, Hu J, Yu R, Zhou X (2015) Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway. J Neuro-Oncol 121:279–288CrossRefGoogle Scholar
  4. Chen Q, Zhang N, Xie R, Wang W, Cai J, Choi KS, David KK, Huang B, Yabuta N, Nojima H, Anders RA, Pan D (2015) Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev 29:1285–1297CrossRefGoogle Scholar
  5. Dai X, Liu H, Shen S, Guo X, Yan H, Ji X, Li L, Huang J, Feng XH, Zhao B (2015) YAP activates the hippo pathway in a negative feedback loop. Cell Res 25:1175–1178CrossRefGoogle Scholar
  6. Fulford A, Tapon N, Ribeiro PS (2018) Upstairs, downstairs: spatial regulation of hippo signalling. Curr Opin Cell Biol 51:22–32CrossRefGoogle Scholar
  7. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, Feng Y, Sun Y, Hou Y, Yang Z, Guan K, Chen H, Zhang L, Ji H (2014) YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun 5(4629)Google Scholar
  8. Geng J, Sun X, Wang P, Zhang S, Wang X, Wu H, Hong L, Xie C, Li X, Zhao H, Liu Q, Jiang M, Chen Q, Zhang J, Li Y, Song S, Wang HR, Zhou R, Johnson RL, Chien KY, Lin SC, Han J, Avruch J, Chen L, Zhou D (2015) Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity. Nat Immunol 16:1142–1152CrossRefGoogle Scholar
  9. Guo C, Wang X, Liang L (2015) LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin Exp Pathol 8:1690–1697Google Scholar
  10. Hergovich A (2016) The roles of NDR protein kinases in Hippo signalling. Genes (Basel) 7Google Scholar
  11. Hoa L, Kulaberoglu Y, Gundogdu R, Cook D, Mavis M, Gomez M, Gomez V, Hergovich A (2016) The characterisation of LATS2 kinase regulation in Hippo-YAP signalling. Cell Signal 28:488–497CrossRefGoogle Scholar
  12. Ji T, Liu D, Shao W, Yang W, Wu H, Bian X (2012) Decreased expression of LATS1 is correlated with the progression and prognosis of glioma. J Exp Clin Cancer Res 31:67CrossRefGoogle Scholar
  13. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D (2006) Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56:450–458CrossRefGoogle Scholar
  14. Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai ZC, Al Hezaimi K, Hakem R, Guan KL, Wang CY (2013) LATS2 suppresses oncogenic Wnt signaling by disrupting beta-catenin/BCL9 interaction. Cell Rep 5:1650–1663CrossRefGoogle Scholar
  15. Malik SA, Khan MS, Dar M, Hussain MU, Shah MA, Shafi SM, Mudassar S (2018) Molecular alterations and expression dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma. Pathol Oncol Res 24:207–214CrossRefGoogle Scholar
  16. Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, Flores F, Yu FX, Halder G, Guan KL (2015) MAP 4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun 6:8357CrossRefGoogle Scholar
  17. Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, Guan KL (2015) A YAP/TAZ-induced feedback mechanism regulates hippo pathway homeostasis. Genes Dev 29:1271–1284CrossRefGoogle Scholar
  18. Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, Carson DA, Guan KL (2016) The hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 167:1525–1539 e1517CrossRefGoogle Scholar
  19. Mou F, Praskova M, Xia F, Van Buren D, Hock H, Avruch J, Zhou D (2012) The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J Exp Med 209:741–759CrossRefGoogle Scholar
  20. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873–883CrossRefGoogle Scholar
  21. Park GS, Oh H, Kim M, Kim T, Johnson RL, Irvine KD, Lim DS (2016) An evolutionarily conserved negative feedback mechanism in the hippo pathway reflects functional difference between LATS1 and LATS2. Oncotarget 7:24063–24075Google Scholar
  22. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S et al (2018) Oncogenic signaling pathways in the cancer genome atlas. Cell 173:321–337 e310CrossRefGoogle Scholar
  23. Sharif AAD, Hergovich A (2018) The NDR/LATS protein kinases in immunology and cancer biology. Semin Cancer Biol 48:104–114CrossRefGoogle Scholar
  24. Stupp R, Tonn JC, Brada M, Pentheroudakis G, Group EGW (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–v193CrossRefGoogle Scholar
  25. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11:1380–1385CrossRefGoogle Scholar
  26. Visser S, Yang X (2010) LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 9:3892–3903CrossRefGoogle Scholar
  27. Wang Y, Pan P, Wang Z, Zhang Y, Xie P, Geng D, Jiang Y, Yu R, Zhou X (2017) beta-catenin-mediated YAP signaling promotes human glioma growth. J Exp Clin Cancer Res 36:136CrossRefGoogle Scholar
  28. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507CrossRefGoogle Scholar
  29. Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R, Xu L, Zhou W, Choi K, Rizvi TA et al (2018) Programming of Schwann cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell 33:292–308 e297CrossRefGoogle Scholar
  30. Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y, Nojima H (2000) Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene LATS/warts. Genomics 63:263–270CrossRefGoogle Scholar
  31. Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL, Xu T (2004) LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol 6:609–617CrossRefGoogle Scholar
  32. Yao F, Liu H, Li Z, Zhong C, Fang W (2015) Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells. Tumour Biol 36:2049–2057CrossRefGoogle Scholar
  33. Yu T, Bachman J, Lai ZC (2013) Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics 195:1193–1196CrossRefGoogle Scholar
  34. Zhang X, Ding Z, Mo J, Sang B, Shi Q, Hu J, Xie S, Zhan W, Lu D, Yang M et al (2014) GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. In: Mol CarcinogGoogle Scholar
  35. Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang Y, Jiang Y, Zhang Y, Fu J, Dong Y, Gao S, Yu R, Zhou X (2016) Expression and significance of hippo/YAP signaling in glioma progression. In: Tumour Biol, vol 37, pp 15665–15676Google Scholar
  36. Zhang C, Wang F, Xie Z, Chen L, Sinkemani A, Yu H, Wang K, Mao L, Wu X (2018) Dysregulation of YAP by the Hippo pathway is involved in intervertebral disc degeneration, cell contact inhibition, and cell senescence. Oncotarget 9:2175–2192Google Scholar
  37. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761CrossRefGoogle Scholar
  38. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev 24:72–85CrossRefGoogle Scholar
  39. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26:54–68CrossRefGoogle Scholar
  40. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16:425–438CrossRefGoogle Scholar
  41. Zhou X, Xie S, Wu S, Qi Y, Wang Z, Zhang H, Lu D, Wang X, Dong Y, Liu G, Yang D, Shi Q, Bian W, Yu R (2017) Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. Neuro-Oncology 19:1628–1639CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Nervous System DiseasesXuzhou Medical UniversityXuzhouPeople’s Republic of China
  2. 2.Brain HospitalAffiliated Hospital of Xuzhou Medical UniversityXuzhouPeople’s Republic of China
  3. 3.The Graduate SchoolXuzhou Medical UniversityXuzhouChina

Personalised recommendations